Diabetes Clinical Trials in China for International Patients
China has active clinical research in Type 1 and Type 2 diabetes, including islet-cell replacement, immune-cell therapy, mesenchymal stem cells, new glucose-lowering drugs and investigational procedures. Finding a trial online, however, is only the first step.
Short answer: some China diabetes studies are currently listed as recruiting, but
“Recruiting” does not mean “open to every foreign patient.” The study team must confirm medical
eligibility, current site status, nationality/residency rules, language and follow-up requirements, and whether
an overseas patient can realistically participate before travel is booked.
✓ Exact registry IDs
✓ Named hospitals/sites
✓ Status freshness shown
✓ No enrollment guarantee
Diabetes Trials in China: At a Glance
China has recruiting early-phase research involving stem-cell-derived islet replacement, including RGB-5088 in Tianjin.
New studies include CNK-UT009 cell therapy in Zibo and an early-phase allogeneic anti-CD7 CAR-T study in Shanghai.
Current studies range from new medicines and remission-focused protocols to endoscopic procedures and cell-therapy research.
Public registries usually describe medical eligibility but often do not establish whether a non-Chinese patient can enroll in practice.
Registry information on this page was reviewed in September 2026. Status can change after publication.
How to Read a China Clinical-Trial Listing
A useful trial listing should answer more than “does this study exist?” For medical travel, five separate questions must be answered before the trial becomes a realistic option.
Is the study current?
Check the recruitment status, last update, estimated completion dates and whether the site itself still shows as recruiting.
Do you fit the protocol?
Diabetes type alone is not enough. Age, HbA1c, C-peptide, disease duration, BMI, complications and prior treatment may matter.
Can a foreign patient apply?
Nationality, residency, language, insurance, companion and follow-up requirements may not appear in the public registry.
What will participation cost?
Protocol-covered treatment does not automatically cover flights, lodging, interpretation, extra tests or non-protocol care.
Current and Recent Diabetes Clinical Trials in China
Status rule: the table below reports what the public registry currently says and whether that status
looks fresh enough to rely on. A patient should never book travel before the hospital or study team confirms that
screening is still open.
| Trial / diabetes type | Approach | China site | Registry status | Who it is broadly aimed at | Foreign-patient access |
|---|---|---|---|---|---|
| NCT06731218 Type 1 · Phase I |
RGB-5088 islet-cell transplantation | Tianjin First Center Hospital, Tianjin | Recruiting Last update posted Sep 2025; estimated enrollment 10. |
Adults 18–60 with T1D; public criteria include stimulated C-peptide <0.3 ng/mL and ≥1 severe hypoglycemia episode in the prior 12 months. | Not established publicly. Must be confirmed with the study site. |
| NCT07051564 Type 1 · investigator-initiated |
CNK-UT009 cell injection; early safety, tolerability and preliminary efficacy research | Zibo Central Hospital, Shandong | Recruiting Last update posted Jul 2025; estimated enrollment 12. |
Adults 18–65 with autoimmune T1D; the public criteria require measurable stimulated C-peptide rather than complete absence of endogenous secretion. | Not established publicly. Site inquiry required. |
| NCT07528105 Type 1 · Early Phase I |
Allogeneic CD7-targeted CAR-T cell injection | Zhongshan Hospital, Fudan University, Shanghai | Recruiting Last update posted Apr 2026; estimated enrollment 9. |
Early-stage Type 1 diabetes under a very small experimental immune-cell protocol focused primarily on safety and preliminary efficacy. | Not established publicly. Must be asked directly. |
| NCT06407297 Type 1 · pediatric UCMSC |
Allogeneic umbilical-cord mesenchymal stem cells plus standard therapy | Shanghai Changzheng Hospital | Unknown status Last verified May 2024; last known status Recruiting; estimated completion May 2026. |
Children/adolescents 8–18 with newly diagnosed Type 1 diabetes under a defined research protocol. | Do not treat as a current route until the hospital reconfirms study status and overseas access. |
| NCT07678866 Type 2 · preliminary study |
Investigational pulse-electric-field ablation system | Shanghai East Hospital | Recruiting Public record current in 2026. |
Adults 18–70 with T2D, HbA1c 7.5–10.5%, BMI 27–40 and suboptimal control under specified treatment conditions. | Not established publicly. Endoscopic procedure and follow-up requirements require direct site confirmation. |
| NCT07599410 Type 2 · Phase II |
HRS9531 oral tablet vs placebo | Beijing Chaoyang Hospital; Qilu Hospital of Shandong University | Not yet recruiting Last update posted May 2026; estimated enrollment 240. |
Adults 18–70 with T2D, HbA1c 7.5–10.5%, BMI 20–40 and inadequate control with lifestyle alone or stable metformin. | No enrollment should be pursued until the registry/site changes to an open recruitment state. |
| NCT07374328 Type 2 · remission-focused |
Semaglutide-based vs sitagliptin-based triple drug regimens | Multicentre China study sponsored by Second Affiliated Hospital of Guangzhou Medical University | Registry says Recruiting — verify now Last verified Jan 2026; estimated completion Aug 31, 2026 has already passed. |
Newly diagnosed T2D, age 18–65, HbA1c ≥9%; primary outcome is diabetes remission rate. | Current recruitment and foreign-patient access must both be reconfirmed before considering this route. |
| NCT07495956 Type 2 · Phase I/II cell therapy |
Clonal fetal mesenchymal stem-cell (cfMSC) therapy | Shenzhen Geno-Immune Medical Institute | Status needs direct verification ClinicalTrials.gov record says Recruiting (last verified Mar 2026); a later third-party tracker reported Active, not recruiting in Aug 2026. |
Adults with established T2D and poor control under conventional treatment; study evaluates feasibility, safety and preliminary efficacy. | Do not assume availability. Ask the study site for current screening status before discussing travel. |
This is a curated medical-travel tracker, not an exhaustive list of all diabetes research in China. We prioritize studies that are clinically relevant to the questions international patients are actually asking: cell/islet replacement, remission, new therapies and difficult-to-control diabetes.
Type 1 Diabetes Trials in China: What Is Being Studied?
Current China Type 1 research is not one single “stem-cell cure” programme. It includes several very different biological strategies, each with its own eligibility, risks and scientific question.
Stem-cell-derived islets
RGB-5088 is an islet-cell replacement approach intended to restore insulin-producing cell function. It is a small Phase I study, not routine care.
CNK-UT009
The Zibo study examines safety, immune-cell effects, C-peptide, HbA1c, CGM metrics and insulin requirement under an early investigator-initiated protocol.
Allogeneic anti-CD7 CAR-T
The Fudan Zhongshan study is an Early Phase I experiment in early-stage T1D, primarily designed to establish safety and preliminary biological effect.
Have Type 1 diabetes?
Our Type 1 guide separates standard insulin/CGM/AID care from islet replacement, immune research and trial eligibility.
Type 2 Diabetes Trials in China: What Is Being Studied?
Type 2 research is broader. The relevant question may be remission, weight/metabolic treatment, a new drug, an investigational procedure or regenerative therapy — not simply “stem cells.”
Combination drug strategies
NCT07374328 explicitly uses diabetes remission rate as its primary outcome in newly diagnosed Type 2 diabetes.
HRS9531 tablet
A Phase II study is registered in Beijing and Jinan but is currently listed as not yet recruiting.
Pulse-electric-field ablation
Shanghai East Hospital is recruiting for an investigational endoscopic-style procedure in selected adults with suboptimal drug control.
cfMSC
A Shenzhen Phase I/II study evaluates clonal fetal mesenchymal stem cells, but its current practical recruitment status should be reconfirmed directly.
Have Type 2 diabetes?
Our Type 2 guide explains remission, weight/metabolic treatment, complications, surgery and experimental research.
Can Foreign Patients Join Diabetes Clinical Trials in China?
Sometimes — but do not infer this from “Recruiting.” A public registry may show medical criteria,
a hospital and a contact person without saying whether non-Chinese citizens, people without local insurance or
patients who cannot remain in China for repeated visits are eligible in practice.
Questions the registry may answer
- Diagnosis and age range
- HbA1c / C-peptide / BMI thresholds
- Prior-treatment requirements
- Main exclusions
- Hospital / study location
- Public recruitment status
Questions the hospital may still need to answer
- Are foreign citizens accepted?
- Is Chinese residency required?
- Can consent and visits be handled in English?
- How long must the patient stay in China?
- How many return visits are required?
- Which costs are covered by the study?
- Can required follow-up be performed abroad?
What Medical Records Are Usually Needed for Trial Screening?
The exact protocol controls eligibility. The records below are a practical pre-screening set that lets a study team quickly understand whether an inquiry is worth pursuing.
Type 1 diabetes
- Age and year diagnosed
- Latest HbA1c
- Fasting / stimulated C-peptide
- Pancreatic autoantibodies if available
- Current insulin dose
- Recent CGM report
- Severe hypoglycemia / DKA history
- Kidney, eye, cardiovascular and transplant history
Type 2 diabetes
- Age, height, weight and BMI
- Year diagnosed
- Latest HbA1c
- C-peptide if available
- Current medications and insulin use
- Kidney and liver function
- Major complications
- Previous metabolic / bariatric treatment
Are Diabetes Clinical Trials in China Free?
Do not assume the whole trip is free. A study may cover an investigational product and
protocol-required procedures, but cost responsibility differs by protocol and site. Flights, hotel, interpretation,
extra tests, non-protocol medical care and companion expenses may remain the patient’s responsibility.
Before travelling, ask for a written answer on which study-related costs are covered, which are not, how long the patient must remain near the study centre, and whether follow-up visits can be completed outside China.
Planning the full budget?
Our cost guide separates Chinese public medical prices, hospital-specific quotes, experimental-treatment costs and travel expenses.
Clinical-Trial Red Flags for International Patients
“Guaranteed enrollment”
The investigator, not a facilitator, decides whether the patient meets the protocol and can participate.
No registry or ethics identifier
If an offer is described as a clinical trial, ask for the exact registration or ethics reference and named site.
Payment presented as trial eligibility
A commercial self-pay package and a clinical study are not the same route. Paying more does not make a patient eligible for a trial.
Old recruitment status
Registries can become stale. Check last verified / last update dates and confirm current screening directly with the site.
No follow-up plan
Early cell and immune studies can require prolonged safety monitoring. “Fly home after treatment” may be incompatible with the protocol.
Paper used as a sales brochure
A published breakthrough does not prove that a separately marketed package is the same treatment or study.
How Parkmega Checks a China Diabetes Trial
Verify the registry record
Exact ID, intervention, site, recruitment status, last update and inclusion/exclusion criteria.
Pre-screen the records
We organize the facts the trial actually asks about; we do not make the medical eligibility decision ourselves.
Ask the study site
Current screening, foreign citizenship, language, required stay, follow-up and which records must be translated.
Plan only after a response
Travel, costs and visa/invitation planning start after the site confirms that the case can realistically proceed.
What to Send Us for a Trial-Access Check
Your medical file
- Type 1 / Type 2 / other diagnosis
- Age and year diagnosed
- Latest HbA1c
- C-peptide and antibodies if relevant
- Current insulin / medication
- Major complications and admissions
- Recent specialist reports
Your trial request
- ClinicalTrials.gov / ChiCTR / other trial ID
- Hospital name if known
- Country of citizenship / residence
- Preferred travel window
- Ability to stay in China for follow-up
- Any message, brochure or quote already received
Found a Diabetes Trial in China and Want to Know Whether You Can Actually Apply?
Send the trial ID and your medical records. We’ll check the public protocol, identify the study site and ask whether the team is still screening and whether an overseas patient can be considered.
✓ No enrollment guarantee
✓ Status rechecked before travel
✓ Hospital/site contacted when appropriate
Related Diabetes Guides
Frequently Asked Questions
Short answers to the questions international patients ask before contacting a China study site.
Are there diabetes clinical trials in China in 2026?
Yes. Public registries list active or recently active Chinese studies in both Type 1 and Type 2 diabetes, including islet-cell replacement, immune-cell therapy, mesenchymal stem cells, new glucose-lowering drugs, remission-focused regimens and investigational procedures. Each study has its own eligibility and recruitment status.
Can foreign patients join diabetes clinical trials in China?
Sometimes, but a public registry listing does not prove overseas-patient acceptance. The study site must confirm medical eligibility, nationality or residency restrictions, language requirements, required time in China and whether follow-up can be completed by an international participant.
What Type 1 diabetes trials are recruiting in China?
As checked in September 2026, ClinicalTrials.gov lists NCT06731218 (RGB-5088 islet-cell transplantation, Tianjin), NCT07051564 (CNK-UT009 cell therapy, Zibo) and NCT07528105 (allogeneic anti-CD7 CAR-T, Fudan Zhongshan Hospital in Shanghai) as recruiting. Status should still be rechecked directly before a patient inquiry.
What Type 2 diabetes trials are active in China?
Examples in 2026 include NCT07678866 at Shanghai East Hospital, which is listed as recruiting for an investigational pulse-electric-field procedure, and NCT07599410, a Phase II HRS9531 tablet study registered in Beijing and Jinan but listed as not yet recruiting. Other records may need status re-verification if their last update is old or an estimated completion date has passed.
Does “Recruiting” mean I am eligible for the trial?
No. “Recruiting” describes the study’s public recruitment status. Eligibility depends on the protocol and the investigator’s assessment. A person may be excluded because of age, HbA1c, C-peptide, BMI, complications, previous treatment, medication, pregnancy risk or many other study-specific criteria.
Are diabetes clinical trials in China free?
Do not assume the entire trip is free. The investigational treatment and protocol-required procedures may be covered according to the study, while flights, lodging, interpretation, extra tests, non-protocol care and companion costs may not be. Cost responsibility must be confirmed with the study site.
What records do I need for diabetes trial screening in China?
At minimum, send your diabetes type, age, year diagnosed, recent HbA1c, current insulin or medication, major complications and the trial ID. Type 1 protocols may also need C-peptide, autoantibodies, CGM data and severe hypoglycemia history; Type 2 protocols may need BMI, C-peptide, renal function and detailed treatment history.
Can Parkmega guarantee that I will be accepted into a trial?
No. Parkmega can organize the medical file, verify the public study record and contact a relevant hospital or study team when appropriate. Only the study investigator can determine medical eligibility and confirm whether the patient can enroll.
Primary Trial Sources
- ClinicalTrials.gov NCT06731218 — RGB-5088, Type 1 diabetes. Phase I, estimated enrollment 10, Tianjin First Center Hospital; public record lists Recruiting. Registry record.
- ClinicalTrials.gov NCT07051564 — CNK-UT009, Type 1 diabetes. Investigator-initiated cell-therapy study, estimated enrollment 12, Zibo Central Hospital; public record lists Recruiting. Registry record.
- ClinicalTrials.gov NCT07528105 — allogeneic anti-CD7 CAR-T, Type 1 diabetes. Early Phase I, estimated enrollment 9, Zhongshan Hospital of Fudan University; public record lists Recruiting and was updated in April 2026. Registry record.
- ClinicalTrials.gov NCT06407297 — UCMSC + standard therapy, newly diagnosed pediatric Type 1 diabetes. Shanghai Changzheng Hospital. ClinicalTrials.gov marks overall status Unknown; last known status was Recruiting, but the record was last verified in May 2024 and estimated study completion was May 2026. Registry record.
- ClinicalTrials.gov NCT07678866 — pulse-electric-field ablation, Type 2 diabetes. Shanghai East Hospital; public record lists Recruiting. Registry record.
- ClinicalTrials.gov NCT07599410 — HRS9531 tablet, Type 2 diabetes. Phase II, Beijing Chaoyang Hospital and Qilu Hospital; public record updated in May 2026 lists Not yet recruiting. Registry record.
- ClinicalTrials.gov NCT07374328 — TRED remission study, newly diagnosed Type 2 diabetes. Public registry says Recruiting, but last verification was January 2026 and the estimated study completion date was August 31, 2026; current status therefore requires direct re-verification. Registry record.
- ClinicalTrials.gov NCT07495956 — cfMSC therapy, Type 2 diabetes. Phase I/II Shenzhen study. ClinicalTrials.gov lists Recruiting based on a March 2026 verification; because later third-party tracking has reported a different operational status, this study should be treated as “verify directly” before any patient inquiry. Registry record.
Update policy: this page should be reviewed whenever a study record changes and at least monthly while it is used as a patient-facing trial tracker. “Last checked” refers to the public records we reviewed; it is not a guarantee that a site will still be screening when a patient contacts it.
Medical note: This page is for medical-travel research and trial navigation. It is not medical advice, a treatment recommendation or a guarantee of clinical-trial enrollment.
Send the Trial ID and Your Medical Records Before You Travel
We’ll verify the public study record, organize the relevant medical information and contact the study site when appropriate to ask whether screening is still open and whether an overseas patient can be considered.